CTCX logo

Carmell Therapeutics (CTCX) Cash From Financing

Annual CFF

$11.16 M
+$7.61 M+214.30%

December 31, 2023


Summary


Performance

CTCX Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherCTCXcash flowmetrics:

Quarterly CFF

$341.70 K
-$2.10 M-86.02%

September 30, 2024


Summary


Performance

CTCX Quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherCTCXcash flowmetrics:

TTM CFF

$1.82 M
-$10.72 M-85.50%

September 30, 2024


Summary


Performance

CTCX TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherCTCXcash flowmetrics:

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

CTCX Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+214.3%-96.9%-84.8%
3 y3 years+833.9%--
5 y5 years+833.9%--

CTCX Cash From Financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+833.9%-96.9%+144.3%-85.5%+6641.0%
5 y5-yearat high+833.9%-96.9%+144.3%-85.5%+6641.0%
alltimeall timeat high+833.9%-96.9%+144.3%-85.5%+6641.0%

Carmell Therapeutics Cash From Financing History

DateAnnualQuarterlyTTM
Sep 2024
-
$341.70 K(-86.0%)
$1.82 M(-85.5%)
Jun 2024
-
$2.44 M(-1349.2%)
$12.54 M(+18.4%)
Mar 2024
-
-$195.70 K(-74.7%)
$10.59 M(-5.1%)
Dec 2023
$11.16 M
-$772.20 K(-107.0%)
$11.16 M(-6.5%)
Sep 2023
-
$11.06 M(+2114.8%)
$11.94 M(+495.0%)
DateAnnualQuarterlyTTM
Jun 2023
-
$499.40 K(+33.2%)
$2.01 M(+35.7%)
Mar 2023
-
$375.00 K(-66.9%)
$1.48 M(+34.0%)
Dec 2022
$3.55 M(+197.1%)
-
-
Sep 2022
-
$1.13 M(-4170.5%)
$1.10 M(-4070.5%)
Jun 2022
-
-$27.80 K
-$27.80 K
Dec 2021
$1.20 M
-
-

FAQ

  • What is Carmell Therapeutics annual cash flow from financing activities?
  • What is the all time high annual CFF for Carmell Therapeutics?
  • What is Carmell Therapeutics annual CFF year-on-year change?
  • What is Carmell Therapeutics quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for Carmell Therapeutics?
  • What is Carmell Therapeutics quarterly CFF year-on-year change?
  • What is Carmell Therapeutics TTM cash flow from financing activities?
  • What is the all time high TTM CFF for Carmell Therapeutics?
  • What is Carmell Therapeutics TTM CFF year-on-year change?

What is Carmell Therapeutics annual cash flow from financing activities?

The current annual CFF of CTCX is $11.16 M

What is the all time high annual CFF for Carmell Therapeutics?

Carmell Therapeutics all-time high annual cash flow from financing activities is $11.16 M

What is Carmell Therapeutics annual CFF year-on-year change?

Over the past year, CTCX annual cash flow from financing activities has changed by +$7.61 M (+214.30%)

What is Carmell Therapeutics quarterly cash flow from financing activities?

The current quarterly CFF of CTCX is $341.70 K

What is the all time high quarterly CFF for Carmell Therapeutics?

Carmell Therapeutics all-time high quarterly cash flow from financing activities is $11.06 M

What is Carmell Therapeutics quarterly CFF year-on-year change?

Over the past year, CTCX quarterly cash flow from financing activities has changed by -$10.72 M (-96.91%)

What is Carmell Therapeutics TTM cash flow from financing activities?

The current TTM CFF of CTCX is $1.82 M

What is the all time high TTM CFF for Carmell Therapeutics?

Carmell Therapeutics all-time high TTM cash flow from financing activities is $12.54 M

What is Carmell Therapeutics TTM CFF year-on-year change?

Over the past year, CTCX TTM cash flow from financing activities has changed by -$10.12 M (-84.76%)